Preliminary counts indicate that NorDiag has received subscriptions for
approximately 19,2 million shares in the subsequent offering closed today. This
represents approximately 240 percent of the total number of offered shares in
the subsequent offering. Allocation of offer shares to the subscribers is
expected to be resolved by the board of directors of NorDiag on or about 18
January 2010. - We are most satisfied with this oversubscription, which we
interpret as shareholders confidence in our recent performance and strategy
going forward, says Mårten Wigstøl.

Reference is made to the stock exchange notice dated 21 December 2009 and the
prospectus dated 21 December 2009 regarding a subsequent offering of up to
8,000,000 offer shares in NorDiag ASA ("NorDiag" or the "Company"), each with a
nominal value of NOK 1.00, at a subscription price of NOK 1.00 per share with
subscription rights for shareholders of the Company as of 25 November 2009,
except shareholders who were invited to participate in the private placement
completed on 25 November 2009.

The subscription period for the subsequent offering expired yesterday, 12
January, 2010 at 17:30 (CET). By the end of the subscription period, preliminary
counts indicate that NorDiag has received subscriptions for approximately 19,2
million shares. This represents approximately 240 percent of the total number of
offered shares in the subsequent offering.

Allocation of offer shares to the subscribers is expected to be resolved by the
board of directors of NorDiag on or about 18 January 2010, following settlement
of trading in the subscription rights in the VPS, in accordance with the
allocation criteria set out in the prospectus. The final result of the
subsequent offering is expected to be published through Oslo Børs' information
system on or about 19 January 2010 and notifications of allocated shares and the
corresponding subscription amount to be paid by each subscriber are expected to
be distributed in letters from VPS on or about the same date. The payment date
for the allocated shares is 21 January 2010.

The offer shares to be issued in the subsequent offering will not be tradable
until the shares have been fully paid and the share capital increase has been
registered in the Norwegian Register of Business Enterprises.

DnB NOR Markets acted as manager in the subsequent offering.


Contact:

Contact:      CEO Mårten Wigstøl        Phone: +47 911 65775
                   CFO Tone Kvåle              Phone: +47 915 19576


About NorDiag:

NorDiag is a biotechnology company developing, manufacturing and marketing
automated solutions (instruments and tests) for sample preparation of DNA from
difficult biological samples. DNA diagnostics give more rapid and precise
answers, and is the fastest growing field within diagnostics. The company's
sample preparation solutions are today used in connection with STI,
tuberculosis, MRSA, respiratory pathogens and viruses on instruments for large
and small laboratories. NorDiag was founded in 2003 and has its headquarters in
Oslo, Norway. The company has offices and laboratories in Stockholm, Sweden, in
West Chester (PA), USA and in Vienna, Austria. The group has today 40.1
man-labour years. NorDiag is listed on Oslo Stock Exchange with ticker NORD.
For further information, please see www.nordiag.com <http://www.nordiag.com>.




This information is subject of the disclosure requirements acc. to §5-12 vphl
(Norwegian Securities Trading Act)


[HUG#1373014]